Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.miravohealthcare.com
Number of Employees: 101
Year Founded: 1983
Total Amount Raised (CAD mm)†: 42.18
Total Rounds of Funding**:8
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada. As of March 14, 2023, Nuvo Pharmaceuticals Inc. operates as a subsidiary of Searchlight Pharma Inc.

Financial Information (Currency: CAD, in mm) 
Total Revenue
72.4
Market Capitalization
15.4
TEV/Total Revenue
1.1x
EBITDA
19.3
Total Enterprise Value
83.0
TEV/EBITDA
4.3x
EBIT
12.3
Cash & ST Invst.
31.3
P/Diluted EPS Before Extra
4.7x
Net Income
15.2
Total Debt
98.9
Price/Tang BV
NM
Capital Expenditure
(0.2)
Total Assets
127.3
Total Debt/EBITDA
5.1x
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Sep-30-2022 TEV and Market Cap are calculated using a close price as of Mar-15-2023

Key Professionals
Name
Title
Ledger, Jesse F.
President & CEO
Burkett, Mary-Jane E.
VP & CFO
Chiasson, Bernard Joseph
VP of Operations & Chief Scientific Officer
Loucaides, Katina K.
VP, Corporate Secretary & General Counsel
Berardelli, Luigi 
Vice President of Sales & Marketing

Key Board Members
Name
Title
Harris, Robert Paul
Non-Executive Chairman
London, John C.
Non-Executive Vice-Chairman
Dobranowski, Anthony E.
Independent Lead Director
Chicoine, Daniel N.
Independent Director
Meuer, Stefan 
Member of Scientific Advisory Board
Ritchie, Mary Campbell
Independent Director
Simon, Lee S.
Member of Scientific Advisory Board
Snow, Anthony Yung
Director
Weil, Dale MacCandlish
Independent Director
Wilkin, Jonathan K.
Member of Scientific Advisory Board
Zinkernagel, Rolf M.
Member of Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
6733 Mississauga Road Suite 800 | Mississauga, ON | L5N 6J5 | Canada
Fax: 905 673 1842

Parent Company
Searchlight Pharma Inc.

Prior Investors
Acqua Wellington Asset Management LLC, Acqua Wellington North American Equities Fund, Ltd., DFJ ePlanet Ventures, L.P., Draper Fisher Jurvetson Fund VII, L.P., ePlanet Capital, Paladin Labs Inc., Red Oak Partners, LLC, Threshold Ventures Management Company, LLC


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Aralez Pharmaceuticals Canada Inc.
Aralez Pharmaceuticals Canada Inc. operates as a specialty pharmaceutical company. The company is based in Mississauga, Canada. Aralez Pharmaceuticals Canada Inc. operates as a subsidiary of Aralez Pharmaceuticals Inc. As of December 31, 2018, Aralez Pharmaceuticals Canada Inc. operates as a subsidiary of Nuvo Pharmaceuticals Inc.

United States and Canada
Pharmaceuticals
-
-
-
ZARS Pharma, Inc.
ZARS Pharma, Inc. manufactures and commercializes topically administered drugs primarily in the area of pain management. Its products include Pliaglis, a topical local anesthetic cream that provides local dermal anesthesia on intact skin prior to painful cosmetic procedures, such as dermatologic laser surgery and dermal filler injections; Synera, a topical patch designed to provide local dermal anesthesia for potentially painful superficial procedures, which includes venous access procedures involving needles and immunization injections of children; and Flexicaine, which is designed to provide rapid dermal analgesia to affected skin for the treatment of post-herpetic neuralgia. The company’s products also comprise Steroid DuraPeel, a phase-changing gel designed to deliver a steroid locally for an extended period of time for the treatment of corticosteroid-responsive dermatoses, including hand dermatitis and psoriasis; Alprazolam Patch, which is used for treating general anxiety and panic disorders; and Risperidone Patch, which delivers risperidone across the skin at a controlled rate for up to three days. ZARS Pharma, Inc. was formerly known as ZARS, Inc. and changed its name to ZARS Pharma, Inc. in July 2007. The company was founded in 1996 and is based in Salt Lake City, Utah. As of May 12, 2011, ZARS Pharma, Inc. operates as a subsidiary of Nuvo Pharmaceuticals Inc.

United States and Canada
Pharmaceuticals
12.00
56.00
11.00
fqubed, Inc.
fqubed, Inc. engages in the development and commercialization of skin modulating materials for pharmaceutical, medical device, and personal care products. Its materials modulate the barrier properties of skin in various ways. The company markets and sells its products in the United States, Europe, Japan, and Pacific Rim. It serves companies in the pharmaceutical, biotechnology, personal-care, and medical device market sectors. The company was founded in 2002 and is based in San Diego, California. As of December 22, 2005, fqubed, Inc. operates as a subsidiary of Nuvo Research, Inc.

United States and Canada
Biotechnology
-
-
-
Nuvo Research AG
Nuvo Research AG, a pharmaceutical company, develops therapeutics by changing macrophage-mediated immune responses to treat immune dysfunction. Nuvo Research AG was formerly known as Dimethaid AG. The company was incorporated in 1986 and is based in Fribourg, Switzerland. It has a manufacturing plant in Wanzleben, Germany. Nuvo Research AG operates as a subsidiary of Nuvo Pharmaceuticals Inc.

Europe
Pharmaceuticals
-
-
-
Dimethaid Immunology Inc

-
-
-
-
-
Global Ex-U.S. Rights To Resultz Of Piedmont Pharmaceuticals LLC
As of January 2, 2018, Global Ex-U.S. Rights To Resultz Of Piedmont Pharmaceuticals LLC was acquired by Nuvo Pharmaceuticals Inc. Global Ex-U.S. Rights To Resultz Of Piedmont Pharmaceuticals LLC comprises pharmaceutical product for head lice treatment and is located in the United States.

United States and Canada
Pharmaceuticals
-
-
-
Global Rights to Resultz Of Piedmont Pharmaceuticals LLC

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Dec-23-2022
Mar-14-2023
Merger/Acquisition
Target
Nuvo Pharmaceuticals Inc.
Searchlight Pharma Inc.
Red Oak Partners, LLC
84.28
Mar-8-2021
-
Shelf Registration
Target
Nuvo Pharmaceuticals Inc.


31.60
Aug-10-2018
Dec-31-2018
Merger/Acquisition
Buyer
Aralez Pharmaceuticals Canada Inc.
Nuvo Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (nka:Old API Wind-down Ltd.)
62.50
Nov-30-2017
-
Buyback
Target
Nuvo Pharmaceuticals Inc.


0.57
Dec-14-2015
Mar-01-2016
Spin-Off/Split-Off
Seller
Crescita Therapeutics Inc. (TSX:CTX)

Nuvo Research Inc. (nka:Nuvo Pharmaceuticals Inc.)
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Mar-16-2023
Delistings
Nuvo Pharmaceuticals Inc. Ordinary Shares to Be Deleted from OTC Equity
Mar-14-2023
M&A Transaction Closings
Searchlight Pharma Inc. completed the acquisition of Nuvo Pharmaceuticals Inc. (TSX:MRV) from Red Oak Partners, LLC and other shareholders.
Mar-07-2023
Special/Extraordinary Shareholders Meeting
Nuvo Pharmaceuticals Inc., Special/Extraordinary Shareholders Meeting, Mar 07, 2023
Mar-07-2023
Shareholder/Analyst Calls
Nuvo Pharmaceuticals Inc. - Shareholder/Analyst Call
Mar-07-2023
Delistings
Nuvo Pharmaceuticals to Be De-Listed from the TSX, Following Completion of the Arrangement

Competitors
Acerus Pharmaceuticals Corporation, Bayer Aktiengesellschaft (XTRA:BAYN), HLS Therapeutics Inc. (TSX:HLS), Pharmascience Inc.

M&A Advisors
Allen & Overy LLP, Bloom Burton Securities Inc., Goodmans LLP


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Allen & Overy LLP, Bloom Burton Securities Inc., Goodmans LLP
Private Placement Advisors
MGI Securities Inc., Paradigm Capital Inc., Vengate Capital Partners Co.
Public Offering Advisors
BDO Canada LLP, Goodmans LLP
Key development Advisor
Bloom Burton & Co. Inc.


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 20, 2023 06:26 AM
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc
Reports
375
MarketLine

Aug 31, 2023 06:01 AM
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
36
GlobalData

Aug 23, 2023 06:44 AM
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
54
MarketLine

Jun 26, 2023 06:01 AM
Nuvo Pharmaceuticals Inc.
Miravo Healthcare
Reports
42
GlobalData

Jun 16, 2023 03:01 AM
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc
Reports
375
GlobalData

Apr 26, 2023 07:13 AM
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc (MRV.TSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
54
GlobalData

Mar 29, 2023 04:48 AM
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc (MRV.TSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
53
CFRA Equity Research

Mar 16, 2023 04:46 AM
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc.
Reports
9
GlobalData

Mar 10, 2023 01:11 AM
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc (MRV.TSE) - Financial Analysis Review
Reports
388
S&P Global Compustat

Mar 02, 2023 02:55 AM
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc 2023_03_02
Reports
16


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Red Oak Partners, LLC

0

-

-

Jun-30-2023



No Data Available.



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Red Oak Partners, LLC
0
(1,917,600)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Alprazolam Patch (Future), Bezalip SR, Blexten, Blexten Pediatric, Cambia, Collatamp G, Development and Quality Assurance/Quality Control Services, Distribution of Durela2, Distribution of NeoVisc1, Fiorinal, Fiorinal C, Flexicaine (Future), Heated Lidocaine/Tetracaine Patch, Ibuprofen Foam (Future), Licensing of HLT Patch, Licensing of Pennsaid, Licensing of Pennsaid 2%, Licensing of Resultz, Licensing of Suvexx/Treximet, Licensing of Vimovo, Licensing of Yosprala, Mical 1 (Future), Mical 2 (Future), MoviPrep, Mutaflor, NeoVisc ONE, NeoVisc+, NRI – ANA (Future), OXO-K993, Oxoferin, PegaLAX, Penecure (Future), Pennsaid, Pliaglis, Proferrin, Research and Contract Services, Resultz, Risperidone Patch (Future), Soriatane, Suvexx/Treximet, Terbinafine Solution (Future), Testing Services, Uracyst, Vimovo, Viskazide, Visken, Yosprala


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Language
Size
Mar-23-2023
Nuvo Pharmaceuticals Inc.
SEDAR
Material Change Report
English
151 KB
Mar-16-2023
Nuvo Pharmaceuticals Inc.
SEDAR
Change in Corporate Structure
English
127 KB
Mar-16-2023
Nuvo Pharmaceuticals Inc.
SEDAR
Securities Acquisition Filings (Early Warning)
English
116 KB
Mar-16-2023
Nuvo Pharmaceuticals Inc.
SEDAR
Documents Affecting the Rights of Security Holders
English
325 KB
Mar-15-2023
Nuvo Pharmaceuticals Inc.
SEDAR
Documents Affecting the Rights of Security Holders
English
2 MB
Mar-15-2023
Nuvo Pharmaceuticals Inc.
SEDAR
Documents Affecting the Rights of Security Holders
English
3 MB
Mar-14-2023
Nuvo Pharmaceuticals Inc.
SEDAR
News Releases
French
52 KB
Mar-14-2023
Nuvo Pharmaceuticals Inc.
SEDAR
News Releases
English
153 KB
Mar-10-2023
Nuvo Pharmaceuticals Inc.
SEDAR
News Releases
English
122 KB
Mar-07-2023
Nuvo Pharmaceuticals Inc.
SEDAR
News Releases
English
41 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Dobranowski B.A., B.Sc., BA, C.A., C.P.A., CA, CPA, M.B.A., MB, Anthony E. (Independent Lead Director)
Mar-14-2023
Common Shares
(70,000)
-
Open Market Disposition
(100.00)
Multiple
-
Mar-14-2023
Common Shares
(769)
-
Open Market Disposition
-
Exchange Announcement
-
Mar-14-2023
Common Shares
(7,050)
-
Open Market Disposition
-
Exchange Announcement
-
Mar-14-2023
Common Shares
(62,181)
-
Open Market Disposition
-
Exchange Announcement
London L.L.B., L.L.M., LLB, LLM, John C. (Non-Executive Vice-Chairman)
Mar-14-2023
Common Shares
(155,786)
-
Open Market Disposition
(100.00)
Multiple
-
Mar-14-2023
Common Shares
(155,313)
-
Open Market Disposition
-
Exchange Announcement
-
Mar-14-2023
Common Shares
(473)
-
Open Market Disposition
-
Exchange Announcement
Chicoine B.Com., B.Comm., C.A., CPA, CA, CPA, Daniel N. (Independent Director)
Mar-14-2023
Common Shares
(235,784)
-
Open Market Disposition
(100.00)
Multiple
-
Mar-14-2023
Common Shares
(223,157)
-
Open Market Disposition
-
Exchange Announcement
-
Mar-14-2023
Common Shares
(12,627)
-
Open Market Disposition
-
Exchange Announcement
Chiasson Ph.D., Bernard Joseph (VP of Operations & Chief Scientific Officer)
Mar-14-2023
Common Shares
(20,603)
-
Open Market Disposition
(100.00)
Multiple
-
Mar-14-2023
Common Shares
(8,118)
-
Open Market Disposition
-
Exchange Announcement
-
Mar-14-2023
Common Shares
(9,485)
-
Open Market Disposition
-
Exchange Announcement
-
Mar-14-2023
Common Shares
(3,000)
-
Open Market Disposition
-
Exchange Announcement
Loucaides M.Sc., LL.B, Katina K. (VP, Corporate Secretary & General Counsel)
Mar-14-2023
Common Shares
(23,126)
-
Open Market Disposition
(100.00)
Multiple
-
Mar-14-2023
Common Shares
(13,855)
-
Open Market Disposition
-
Exchange Announcement
-
Mar-14-2023
Common Shares
(8,400)
-
Open Market Disposition
-
Exchange Announcement
-
Mar-14-2023
Common Shares
(871)
-
Open Market Disposition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Harris, Robert Paul
Non-Executive Chairman
-
905 673 1842

London, John C.
Non-Executive Vice-Chairman
-
905 673 1842

Dobranowski, Anthony E.
Independent Lead Director
-
905 673 1842

Chicoine, Daniel N.
Independent Director
-
905 673 1842

Meuer, Stefan 
Member of Scientific Advisory Board
-
905 673 1842

Ritchie, Mary Campbell
Independent Director
-
905 673 1842

Simon, Lee S.
Member of Scientific Advisory Board
-
905 673 1842

Snow, Anthony Yung
Director
-
905 673 1842
asnow@cordblood-america.com
Weil, Dale MacCandlish
Independent Director
-
905 673 1842

Wilkin, Jonathan K.
Member of Scientific Advisory Board
-
905 673 1842

Zinkernagel, Rolf M.
Member of Scientific Advisory Board
-
905 673 1842

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Ledger, Jesse F.
President & CEO
-
905 673 1842
-
Burkett, Mary-Jane E.
VP & CFO
-
905 673 1842

Chiasson, Bernard Joseph
VP of Operations & Chief Scientific Officer
-
905 673 1842

Loucaides, Katina K.
VP, Corporate Secretary & General Counsel
-
905 673 1842
-
Berardelli, Luigi 
Vice President of Sales & Marketing
-
905 673 1842

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
